OBJECTIVES:  Dapagliflozin is shown to be effective in improving glycemic control and blood pressure for patients with T2D and hypertension in randomized trials. This study used real-world electronic medical record (EMR) data to compare outcomes among T2D patients with hypertension treated with dapagliflozin (D) + metformin (M), with or without other OAD (D+M±OAD), versus metformin with other OAD (M+OAD). METHODS:  Adult patients with T2D on metformin and either dapagliflozin (±OAD) or other OAD as add-on therapy from 01/01/14 to 02/28/15 were identified in a US EMR database, with the date of first prescription for D (D+M±OAD) or other OAD (M+OAD) as the index date. Patients were observed for 12 months before the index date (baseline) and 12 months after (follow-up). Patients were required to have ≥1 diagnosis for hypertension or a prescription for ACE inhibitor or ARB during baseline. Outcomes included change in A1C, systolic and diastolic blood pressure (SBP/DBP), and weight from baseline to follow-up. RESULTS:  A total of 421 D+M±OAD patients (mean±SD age 56.5±10.4 y, 46.8% women) and 469 M+OAD patients (age 57.0±11.8 y, 43.9% women) were identified. Mean baseline A1C was 8.8% for D+M±OAD and 8.7% for M+OAD (p=0.64). DPP-4i (39% for D+M±OAD and 49% for M+OAD, p<0.01) and sulfonylureas (38% for D+M±OAD and 42% for M+OAD, p=0.22) are common OADs during baseline. Compared with M+OAD patients, D+M±OAD patients had a greater reduction in A1C (mean ‒1.2% vs ‒0.6%, p<0.01), SBP (‒4.6 vs ‒1.1 mmHg, p=0.01) and DBP (‒2.7 vs ‒0.6 mmHg, p<0.01) from baseline to follow-up. Change in weight was not significantly different (-1.6 vs. -0.9 kg, p=0.06). CONCLUSIONS:  In clinical practice, patients receiving D+M±OAD had greater reductions in A1C and BP versus patients on M+OAD among T2D patients with hypertension. This study supports the use of dapagliflozin as add-on therapy to metformin for such patients.